MPPE1 and infection: In addition to the applications against infections and tumors, the vast body of work obtained from the animal disease models described above suggests the targeted antigen delivery to tolerogenic cDC1 as possible new efficacious strategies for corresponding therapies in patients with autoimmune diseases, such as MS.